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ReviewProtein Tyrosine Phosphatases
in the Human Genome
now led to the emerging recognition that PTPs play
specific and active, even dominant, roles in setting the
levels of tyrosine phosphorylation in cells and in the
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regulation of many physiological processes (Fischer etJack Dixon,4 and Tomas Mustelin1,*
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PTPs is the clarification of the set of genes in the humanLa Jolla, California 92037
genome that encode PTPs. This knowledge will allow3 Molecular and Cell Biology Laboratory
for a more global approach to key questions in the PTPSalk Institute
field and the regulation of tyrosine phosphorylation-10010 North Torrey Pines Road
dependent cellular processes in health and disease.La Jolla, California 92037
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Starting with the amino acid sequence of all publishedUniversity of California, San Diego
PTPs, we used conserved catalytic motifs and wholeBasic Science Building
PTP domains to search the publicly available databases,9500 Gilman Drive
as well as the SEED database, for genes encoding PTPsLa Jolla, California 92093
or PTP-like genes. Two of our novel PTPs were also
found in the Celera and Incyte databases. The genomic
locus, exon-intron structure, expression data, andTyrosine phosphorylation is catalyzed by protein tyro-
mouse orthologs were clarified for each PTP. Previouslysine kinases, which are represented by 90 genes in
unpublished PTPs were subjected to a more thoroughthe human genome. Here, we present the set of 107
investigation to verify that they represented bona fidegenes in the human genome that encode members of
expressed genes with orthologs in the mouse and otherthe four protein tyrosine phosphatase (PTP) families.
organisms. Many of these genes have also recently beenThe four families of PTPases, their substrates, struc-
experimentally verified in our laboratories. The resultsture, function, regulation, and the role of these en-
of this work are a list (Table 1) of all genes in the humanzymes in human disease will be discussed.
genome that encode PTP family members, here defined
as all known protein tyrosine phosphatases plus all pro-Introduction
teins that contain a domain homologous to the catalyticTyrosine phosphorylation is a fundamental mechanism
domain of these known PTPs. The list contains 107for numerous important aspects of eukaryote physiol-
genes, 105 of which have a mouse ortholog (one ofogy, as well as human health and disease (Hunter, 1987;
the missing genes has a rat ortholog). In addition, weMustelin et al., 2002a, 2002b). Compared to protein
estimate that there are at least as many PTP pseu-phosphorylation in general, phosphorylation on tyrosine
dogenes and there are a few bona fide genes (e.g.,is extensively utilized only in multicellular eukaryotes.
paladin, KIAA1274) that encode proteins that contain
Tyrosine phosphorylation is used for communication be-
incomplete or distant PTP-like domains. Of the 107 hu-
tween and within cells, the shape and motility of cells,
man genes, 106 are covered by expressed sequence
decisions to proliferate versus differentiate, cellular pro- tags (ESTs). The only gene lacking EST coverage is
cesses like regulation of gene transcription, mRNA pro- DUSP27 (DUPD1), which earlier was predicted to en-
cessing, and transport of molecules in or out of cells. code a phosphatase with an N-terminal cyclophilin-like
Tyrosine phosphorylation also plays an important role in domain. We have been able to amplify a partial cDNA
the coordination of these processes among neighboring of this gene from testis and muscle mRNA, demonstra-
cells in embryogenesis, organ development, tissue ho- ting that this gene, too, is expressed. DUSP27 has four
meostasis, and the immune system. Abnormalities in exons and is located at 10q22.3 adjacent to DUSP13
tyrosine phosphorylation play a role in the pathogenesis at 10q22.2, which in fact consists of two phosphatase
of numerous inherited or acquired human diseases from genes, which we designate as DUSP13A and DUSP13B
cancer to immune deficiencies. (encoding BEDP and TMDP, respectively), which are
Although it is generally agreed that tyrosine phosphor- similar to the catalytic domain of DUSP27. In the mouse
ylation is regulated by the equal and balanced action genome, the corresponding location on chromosome
of protein tyrosine kinases (PTKs) and protein tyrosine 14 also contains three PTP genes in tandem, although
phosphatases (PTPs), proportionately much more re- the sequence of DUSP27 is incomplete. In the chimpan-
search has focused on PTKs. This is partly for historical zee genome, there is also a DUSP27 gene, which is 99%
reasons: the first PTP was purified (Charbonneau et al., identical to the human within the four exons, but differs
1989) and cloned (Guan et al., 1990) ten years after the in the length of some introns. Thus, it appears that an
first PTK (Czernilofsky et al., 1980). Recent findings have ancestral gene was triplicated (or duplicated twice) be-
fore mice and primates diverged during the Cretaceous,
144–165 million years ago.*Correspondence: tmustelin@burnham-inst.org
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Table 1. The Set of PTP Genes in the Human Genome
Gene Protein, Synonyms Chr. Loc. ESTs Mouse
A. Class I Cys-Gased PTPs (99 Genes)
A. 1. Classical PTPs (38 Genes)
A. 1. 1. Transmembrane Classical PTPs (21 Genes)
1. PTPRA RPTP 20p13 YES YES
2. PTPRB RPTP 12q15-q21 YES YES
3. PTPRC CD45, LCA 1q31-q32 YES YES
4. PTPRD RPTP 9p23-p24.3 YES YES
5. PTPRE RPTP 10q26 YES YES
6. PTPRF LAR 1p34 YES YES
7. PTPRG RPTP 3p21-p14 YES YES
8. PTPRH SAP1 19q13.4 YES YES
9. PTPRJ DEP1, CD148, RPTP 11p11.2 YES YES
10. PTPRK RPTP 6q22.2-23.1 YES YES
11. PTPRM RPTP 18p11.2 YES YES
12. PTPRN IA-2, Islet cell antigen 512 2q35-q36.1 YES YES
13. PTPRN2 PTPRP, RPTP	, IA-2, phogrin, 7q36 YES YES
14. PTPRO GLEPP1/PTP-U2/PTPRO
 12p13.3-p13.2 YES YES
isoforms A/B/C
15. PTPRQ PTPS31 12q21.31 YES YES
16. PTPRR PTP-SL, PCPTP,PTPBR7, 12q15 YES YES
PC12-PTP1
17. PTPRS RPTP 19p13.3 YES YES
18. PTPRT RPTP 20q12-q13 YES YES
19. PTPRU PTPJ/PTP-U1/PTPRomicron 1p35.3-p35.1 YES YES
isoforms 1/2/3
20. PTPRV OST-PTP 1q32.1 YES YES
21. PTPRZ RPTP 7q31.3 YES YES
A. 1.2. NRPTPs (17 Genes)
22. PTPN1 PTP1B 20q13.1-13.2 YES YES
23. PTPN2 TCPTP, MPTP, PTP-S 18p11.3-11.2 YES YES
24. PTPN3 PTPH1 9q31 YES YES
25. PTPN4 PTP-MEG1, TEP 2q14.2 YES YES
26. PTPN5 STEP 11p15.1 YES YES
27. PTPN6 SHP1, PTP1C, SH-PTP1, 12p12-13 YES YES
HCP
28. PTPN7 HePTP, LCPTP 1q32.1 YES YES
29. PTPN9 PTP-MEG2 15q23 YES YES
30. PTPN11 SHP2, SH-PTP2, Syp, 12q24.1 YES YES
PTP1D, PTP2C, SH-PTP3
31. PTPN12 PTP-PEST, PTP-P19, 7q11.23 YES YES
PTPG1)
32. PTPN13 PTP-BAS, FAP-1, PTP1E, 4q21.3 YES YES
RIP, PTPL1, PTP-BL
33. PTPN14 PTP36, PEZ, PTPD2 1q32.2 YES YES
34. PTPN18 PTP-HSCF, PTP20, BDP 2q21.2 YES YES
35. PTPN20 TypPTP 10q11.22 YES YES
36. PTPN21 PTPD1, PTP2E, 14q31.3 YES YES
PTP-RL10
37. PTPN22 LYP, PEP 1p13.3-p13.1 YES YES
38. PTPN23 HD-PTP, HDPTP, PTP- 3p21.3 YES YES
TD14, KIAA1471,
DKFZP564F0923
A. 2. DSPs or VH1-like (61 Genes)
A. 2. 1. MKPs (11 Genes)
39. DUSP1 MKP-1, 3CH134, PTPN10, 5q34 YES YES
erp, CL100/ HVH1
40. DUSP2 PAC-1 2q11 YES YES
41. DUSP4 MKP-2, hVH2/TYP1 8p12-p11 YES YES
42. DUSP5 hVH3/B23 10q25 YES YES
43. DUSP6 PYST1, MKP-3/rVH6 12q22-q23 YES YES
44. DUSP7 PYST2, B59, MKP-X 3p21 YES YES
45. DUSP8 hVH5, M3/6, HB5 11p15.5 YES YES
46. DUSP9 MKP-4, Pyst3 Xq28 YES YES
47. DUSP10 MKP-5 1q41 YES YES
48. DUSP16 MKP-7, MKP-M 12p13 YES YES
49. MK-STYX MK-STYX 7q11.23 YES YES
(continued)
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Table 1. Continued
Gene Protein, Synonyms Chr. Loc. ESTs Mouse
A. 2. 2. Atypical DSPs (19 Genes)
50. DUSP3 VHR, T-DSP11 17q21 YES YES
51. DUSP11 PIR1 2p13.1 YES YES
52. DUSP12 HYVH1, GKAP, 1q21-q22 YES YES
LMW-DSP4
53. DUSP13Aa BEDP 10q22.2 YES YES
54. DUSP13Ba TMDP, TS-DSP6 10q22.2 YES YES
55. DUSP14 MKP6, MKP-L 17q12 YES YES
56. DUSP15 VHY, Q9H1R2 20q11.21 YES YES
57. DUSP18 DUSP20, LMW-DSP20 22q12.2 YES YES
58. DUSP19 DUSP17, SKRP1, LDP-2, 2q32.1 YES YES
TS-DSP1
59. DUSP21 LMW-DSP21, BJ-HCC-26 Xp11.4-p11.23 YES YES
tumor antigen
60. DUSP22 VHX, MKPX, JSP1, LMW- 6p25.3 YES YES
DSP2, TS-DSP2, JKAP
61. DUSP23 MOSP, similar to RIKEN 11p11.2 YES YES
cDNA 2810004N20
62. DUSP24 MGC1136 8p12 YES YES
63. DUSP25 VHZ, FLJ20442, LMW-DSP3 1q23.1 YES YES
64. DUSP26 VHP, “similar to RIKEN 2q37.3 YES YES
cDNA 0710001B24”
65. DUSP27b DUPD1, FMDSP, “similar 10q22.3 NOc YES
to cyclophilin”
66. EPM2A Laforin 6q24 YES YES
67. RNGTT mRNA capping enzyme 6q16 YES YES
68. STYX STYX 14 YES YES
A. 2. 3. Slingshots (3 Genes)
69. SSH1 SSH1, slingshot 1 12q24.12 YES YES
70. SSH2 SSH2, slingshot 2 17q11.2 YES YES
71. SSH3 SSH3, slingshot 3 11q13.1 YES YES
A. 2. 4. PRLs (3 Genes)
72. PTP4A1 PRL-1 6q12 YES YES
73. PTP4A2 PRL-2, OV-1 1p35 YES YES
74. PTP4A3 PRL-3 8q24.3 YES YES
A. 2. 5. CDC14s (4 Genes)
75. CDC14A CDC14A 1p21 YES YES
76. CDC14B CDC14B 9q22.33 YES YES
77. CDKN3 KAP 14q22 YES YES
78. PTP9Q22 PTP9Q22 9q22.32 YES YES
A. 2. 6. PTENs (5 Genes)
79. PTEN PTEN, MMAC1, TEP1 10q23.3 YES YES
80. TPIP TPIP, TPTE and PTEN 13q12.11 YES YES
homologous
81. TPTE PTEN-like, PTEN2 21p11 YES YES
82. TNS Tensin 2q35-q36 YES YES
83. TENC1 C1-TEN, TENC1, 12q13.13 YES YES
KIAA1075
A. 2. 7. Myotubularins (16 Genes)
84. MTM1 myotubularin Xq28 YES YES
85. MTMR1 MTMR1 Xq28 YES YES
86. MTMR2 MTMR2 11q22 YES YES
87. MTMR3 MTMR3, FYVE-DSP1 22q12.2 YES YES
88. MTMR4 MTMR4, FYVE-DSP2 17q22-q23 YES YES
89. MTMR5 MTMR1, SBF1 22q13.33 YES YES
90. MTMR6 MTMR6 13q12 YES YES
91. MTMR7 MTMR7 8p22 YES YES
92. MTMR8 MTMR8 Xq11.2 YES NO
93. MTMR9 MTMR9, LIP-STYX 8p23-p22 YES YES
94. MTMR10 MTMR10 15q13.1 YES NOd
95. MTMR11 MTMR11CRA / 1q12.3 YES YES
96. MTMR12 MTMR12, 3-PAP 5p13.3 YES YES
97. MTMR13 MTMR13, SBF2, CMT4B2 11p15.3 YES YES
98. MTMR14 FLJ22075, hJumpy, 3p26 YES YES
hEDTP
99. MTMR15 KIAA1018 15q13.1 YES YES
(continued)
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Table 1. Continued
Gene Protein, Synonyms Chr. Loc. ESTs Mouse
B. Class II Cys-Based PTPs (1 Gene)
100. ACP1 LMPTP, low Mr PTP, 2p25 YES YES
LMWPTP, BHPTP
C. Class III Cys-Based PTPs (3 Genes)
101. CDC25A CDC25A 3p21 YES YES
102. CDC25B CDC25B 20p13 YES YES
103. CDC25C CDC25C 5q31 YES YES
D. Asp-Based PTPs (4 Genes)
104. EYA1 Eya1 8q13.3 YES YES
105. EYA1 Eya2 20q13.1 YES YES
106. EYA1 Eya3 1p36 YES YES
107. EYA1 Eya4 6q23 YES YES
107. Total
Includes all known PTPs in the published literature, verified PTPs or dual-specificity phosphatases in public data bases, and ORFs found by
iterative BLAST searches with all the other sequences to find related genes and to assign alternatively spliced forms to the correct genes.
To exclude synonyms, splice variants, and incorrectly assembled sequences, a data base with the amino sequences was created. To exclude
pseudogenes, EST and other expression data bases were consulted, and the exon-intron structures and chromosomal locations of every
gene were determined.
a the human DUSP13 gene contains two DSP genes: DUSP13A (BEDP; 3 exons), two noncoding exons, followed by DUSP13B (TMDP; three
exons). In the mouse, the two genes are designated as separate genes.
b formerly DUPD1, but does not contain an N-terminal cyclophilin domain, as originally annotated. The mouse ortholog also lacks cyclophilin
domain. Thus, the name DUPD1 is a misnomer.
c we have verified its expression by PCR amplification of a partial cDNA.
d there is a rat homolog, suggesting that a mouse homolog probably does exist.
While the 38 classical PTPs have all been published ning et al., 2002). However, a direct comparison of the
two numbers, 107 and 90, respectively, is not completely(reviewed in Andersen et al. [2004]), as many as nine of
the 107 human PTP genes have not been previously fair: of the 107 PTP genes, 11 are catalytically inactive,
2 dephosphorylate mRNA, and 13 dephosphorylate ino-reported (Supplemental Table S1 at http://www.cell.
com/cgi/content/full/117/6/699/DC1), although their ge- sitol phospholipids. Thus, 81 PTPs are active protein
phosphatases with the ability to dephosphorylate phos-nomic loci, exon/intron structure, and, in most cases,
their homology to PTPs were recognized in databases. photyrosine. Of the 90 PTKs, 85 are through to be cata-
lytically active. Thus, the numbers of active PTPs andThese genes include six small phosphatases, DUSP15,
DUSP27 (DUPD1), and four genes for which we propose PTKs are very similar and one can therefore assume
that they have comparable substrate specificities. Boththe genomic designations DUSP23, DUSP24, DUSP25,
and DUSP26. The protein encoded by DUSP15 is a cata- types of enzymes also display comparable tissue distri-
bution patterns, from ubiquitous to cell type restricted,lytically active PTP we term VHY (VH1-related member
Y; Alonso et al., 2004), closely related to VHX encoded so that individual cells express 30%–60% of the entire
complement of PTPs and PTKs. Neuronal and hemato-by DUSP22. The 150 amino acid residue VHZ (VH1-
related member Z) encoded by DUSP25 is the smallest poietic cells may express even higher portions of all
PTPs. That individual PTPs have nonredundant func-of all catalytically active PTPs (Alonso et al., 2004) and
is remarkably well conserved through evolution and tions is also well illustrated by the unique phenotypes
of many of the reported gene deletions in mice. Foreven has a 147 amino acid homolog in Thermococcus
kodakaraensis, which is 30.3% identical and 49.7% simi- example, deletion of PTPN22 (PTPN8 in the mouse)
causes excessive expansion of memory T lymphocytes,lar over 145 residues. We have verified the existence of
a 16 kDa VHZ protein in human cells by immunoblotting. prolonged secondary immune responses, and autoim-
munity (Hasegawa et al., 2004). A polymorphism in theThe novel PTPs also include two myotubularin-related
proteins, for which we propose the genomic designation human PTPN22 gene also correlates with autoimmune
diabetes in humans (Bottini et al., 2004). Other humanMTMR14 and MTMR15. The former is the human or-
tholog of the Sarcophaga peregrina egg-derived tyro- diseases caused by mutations in PTP genes (see discus-
sion below) also support the notion that individual PTPssine phosphatase (Yamaguchi et al., 1999) and the Dro-
sophila melanogaster gene jumpy (Seroude et al., 2002), have unique and important functions.
the mutation of which causes a muscle defect character-
ized by excessive vibrations of the flight muscles (J.D. Classification of the 107 PTPs into Four Families
Based on the amino acid sequences of their catalyticand M.J. Wishart, unpublished observation). MTMR15
encodes a catalytically inactive member of the myotubu- domains, the PTPs can be grouped into four separate
families, each with a range of substrate specificitieslarin group.
(Figure 1). Class I cysteine-based PTPs constitute by
far the largest family and contain the 38 well-knownWhy So Many PTPs?
The number of genes in the human genome that encode “classical” PTPs (Andersen et al., 2004), which are
strictly tyrosine specific and all have mouse orthologs,members of the PTP families is higher than anticipated
and exceeds the number of genes encoding PTKs (Man- and the 61 VH1-like, “dual-specific” protein phospha-
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Figure 1. Classification and Substrate Speci-
ficity of PTPs
The PTP families are color coded: class I Cys-
based PTPs (green), class II Cys-based PTPs
(pale yellow), class III Cys-based PTPs (pale
blue), and Asp-based PTPs (pink). The sub-
strate specificity of each group or class of
PTPs is listed.
tases (DSPs), which is the most diverse group in terms ties of the large family of hydrolases to which the Eya
PTPs belong will require extensive analysis. Here, onlyof substrate specificity (Figure 1). All Class I enzymes
have evolved from a common ancestor, based upon the four Eya proteins are included because they were
shown experimentally to be PTPs.their similar structural folds for classical PTPs, DSPs,
and other VH1-like enzymes. The single class II cysteine-
based PTP in humans is a tyrosine-specific low Mr en- Class I Cysteine-Based PTPs
The 99 class I cysteine-based family of PTPs can bezyme, the origin of which appears to be more ancient
than class I PTPs: representatives of this family are further classified into several subfamilies based on do-
main architecture and the degree of homology betweenfound in a all major phyla, including plants, numerous
prokaryotes, and archea. Class II PTPs are structurally catalytic domains. The 38 strictly tyrosine-specific “clas-
sical PTPs” can be divided into transmembrane, recep-related to bacterial arsenate reductases. Class III cyste-
ine-based PTPs are tyrosine/threonine-specific phos- tor-like enzymes (RPTPs), and the intracellular, nonre-
ceptor PTPs (NRPTPs). They are represented in thephatases that most likely evolved from a bacterial rho-
danese-like enzyme. They are only represented by the human genome by 21 and 17 genes, respectively (Ander-
sen et al., 2004). As is the case for the protein kinases,three p80Cdc25 cell cycle regulators. Interestingly, a group
of class I PTPs contain a catalytically inactive rho- the number of PTP catalytic domains encoded by the
genome is greater than the number of PTP genes be-danese-like domain, referred to as the CDC25 homology
(CH2) domain. Despite similarities in catalytic mecha- cause many of the RPTPs have tandem catalytic do-
mains. The 61 VH1-like enzymes are much more diversenism (Guan and Dixon, 1991) and active site structure
(Barford et al., 1994; Yuvaniyama et al., 1996; Su et al., and can be divided into several subgroups, which share
much less sequence identity with each other than the1994; Fauman et al., 1998), class I, II, and III cysteine-
based PTPs evolved independently. Nevertheless, a RPTPs do with the NRPTPs. Eleven of the 61 VH1-like
PTPs encoded by the human genome are specific forstructural comparison indicates that they may have orig-
inated from an ancestral fold by rearrangment of ele- the mitogen-activated protein (MAP) kinases Erk, Jnk,
and p38 (Alonso et al., 2003a; Keyse, 1998; Saxenaments. In contrast, the fourth family of PTPs use a differ-
ent catalytic mechanism with a key aspartic acid and and Mustelin, 2000). These MAP kinase phosphatases
(MKPs) are characterized by dual phosphothreonine anddependence on a cation. This family contains the Eya
proteins, which were recently discovered to be tyro- phosphotyrosine specificity and the presence of a CH2
region and other MAP kinase targeting motifs (Alonsosine-, or dual serine- and tyrosine-specific protein phos-
phatases (Tootle et al., 2003; Rayapureddi et al., 2003; et al., 2003b; Bordo and Bork, 2002). Another subgroup
of DSPs, which we have referred to as the “atypical”Li et al., 2003). Determination of the substrate specifici-
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DSPs (Alonso et al., 2003b), includes a number of poorly The Class III Cysteine-Based PTPs
characterized enzymes that lack specific MAP kinase These rhodanese-derived PTPs comprise three cell cy-
targeting motifs and tend to be much smaller enzymes, cle regulators, CDC25A, CDC25B, and CDC25C, in hu-
less than 250 amino acid residues. The first DSP to be mans. Their function is to dephosphorylate Cdks at their
cloned, the VH1 protein from Vaccinia virus (Guan et al., inhibitory dually phosphorylated N-terminal Thr-Tyr mo-
1991), is related to this group, as are the human VHR tifs, a reaction that is required for activation of these
(Ishibashi et al., 1992) and a number of genes given kinases to drive progression of cells through the cell
the genomic designations DUSP11, DUS13, DUSP14, cycle (Honda et al., 1993). CDC25s are themselves regu-
DUSP15, DUSP18, DUSP19, DUSP21, DUSP22, and lated by phosphorylation. It is curious that a unique type
others. While VH1 has been reported to dephosphory- of PTP evolved to serve regulation of the cell cycle,
late both MAP kinases and Stat1 (Najarro et al., 2001), instead of class I or class II enzymes, which presumably
and VHR can dephosphorylate Erk and Jnk in 293T cells already existed at the time. Interestingly, the budding
(Todd et al., 1999) and T cells (Alonso et al., 2001, 2003b), yeast cell cycle can function in the absence of Cdc28
it appears that many of these small atypical DSP have Tyr-15 phosphorylation, and so this layer of regulation
functions unrelated to MAP kinases. A true outlier is PIR may have been a later addition. In other words, CDC25
(DUSP11), which dephosphorylates mRNA (Deshpande appears to have entered cell cycle regulation hand in
et al., 1999). hand with tyrosine phosphorylation of the Cdks. Alterna-
The three slingshots (SSH1, SSH2, and SSH3) and the tively, it is possible that an ancestral CDC25 already
three PRLs (PRL-1, PRL-2, and PRL-3) are very poorly acted as a rhodanese-type enzyme on Cdks and was
understood, while the CDC14 group, which includes transformed into a phosphatase when Cdk tyrosine/
KAP, is involved in dephosphorylation of the Cdk activa- threonine phosphorylation evolved. This possibility
tion loop phospho-Thr and inactivation of cyclin-depen- would better explain why CDC25, rather than an existing
dent kinases and in exit from mitosis (Visintin et al., PTP, was utilized.
1998). Finally, the two last subgroups of DSPs, the
PTENs (5 genes) and myotubularins (16 genes), have Asp-Based PTPs
evolved to specifically dephosphorylate the D3-phos- We have listed only the four Eya genes as members of
phate of inositol phospholipids (Wishart and Dixon, the Asp-based PTPs because they have recently been
2002). Enzymes with this specificity are present also shown to have Tyr/Ser phosphatase activity (Tootle et
in yeast. While PTEN dephosphorylates phosphatidyl- al., 2003; Rayapureddi et al., 2003; Li et al., 2003). It is
inositol-3,4,5-trisphosphate at the plasma membrane, clear that this is a much larger family of enzymes, which
the myotubularins primarily dephosphorylate phospha- play important roles in development (Tootle et al., 2003;
tidylinositol-3-phosphate on internal cell membranes Rayapureddi et al., 2003; Li et al., 2003, Satow et al.,
(Wishart and Dixon, 2002). Both groups also contain 2002), sodium stress in yeast (Siniossoglou et al., 2000),
catalytically inactive members. and nuclear morphology (Siniossoglou et al., 1998). RNA
polymerase II C-terminal domain phosphatase is also a
The Class II Cysteine-Based PTPs member of this family. However, a clear and structurally
This family is represented in the human genome by a based definition of this family of enzymes will be needed
single gene, referred to as ACP1, which encodes the before the human gene complement of Asp-based phos-
18 kDa low Mr phosphatase (LMPTP). Related class II phatases can be more accurately determined.
enzymes are widely distributed in living organisms with
most bacterial genomes encoding at least one member
Modular Structure of PTPsof this family, which are remarkably well conserved
One of the most striking features of the PTP familiesthrough evolution. For example, the human LMPTP is
(Figure 2) is that most enzymes consist of combinations31% identical to the corresponding protein in Saccharo-
of modular domains. At least 79 of the 107 PTPs containmyces cerevisiae and 39% identical to the YfkJ protein
at least one additional motif or domain (Table 2) out-in Bacillus subtilis. Despite the paucity of tyrosine phos-
side of their catalytic PTP domain. Many of the domainsphorylation in prokaryotes, the bacterial class II PTPs
are protein-protein interaction or phospholipid bindingare bona fide tyrosine-specific phosphatases and in
modules. In this respect, PTPs resemble the PTKs (Man-many cases dephosphorylate tyrosine “autokinases” in-
ning et al., 2002), but they differ markedly from the ser-volved in regulation of capsule polysaccharide synthe-
ine/threonine-specific protein phosphatases. In PTKs,sis. This may represent the ancestral form of tyrosine
protein-protein interaction domains serve two distinctphosphorylation as a mechanism by which cells sense
purposes: regulation and targeting to substrates and/ortheir extracellular environment, from which receptor
subcellular compartments. This appears to be the casePTKs and the counterbalancing PTPs may have evolved.
also for PTPs, although many of the domains in PTPsAlthough the human LMPTP can dephosphorylate a
are still poorly understood. The set of domains found innumber of tyrosine kinases and their substrates, its
PTPs are listed in Table 2 and they include domainsphysiological function is still unclear. The preservation
that bind specific domains or motifs in other proteinsof a class II PTP through evolution to humans and the
(unphosphorylated or phosphorylated), cellular mem-correlation of allelic variants of LMPTP with many com-
branes, the cytoskeleton, or specific phospholipids.mon human diseases (Bottini et al., 2002), such as rheu-
It is interesting to note that the set of protein domainsmatoid arthritis, asthma, diabetes, cardiomyopathy, and
found in PTPs is only partly overlapping with those foundAlzheimer’s disease, indicate that LMPTP likely is in-
in PTKs (Manning et al., 2002). While many PTKs havevolved in the regulation of one or several fundamental
processes in cell physiology. SH3 and SH2 domains, often in combinations, such as
Review
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Figure 2. Domain Structure of All PTPs
Schematic view of the domain composition of all members of the four PTP families, which are in color coded areas as in Figure 1. Abbreviations
as in Table 2, and: coil, coiled-coil domain; GB, glycogen binding; mRC, mRNA capping; PBM, PDZ binding motif; pepN, N-terminal peptidase-
like; PH-G, pleckstrin homology-“GRAM” domain; Pro-rich, proline-rich; Sec14, Sec14p homology (or CRAL/TRIO). In addition, a small black
box signifies transmembrane stretch and a red cross over a PTP domain signifies catalytically inactive domain.
Cell
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Table 2. Other Domains in PTPs
Domain, Motifa PTP
BRO HD-PTP
C1 C1-ten
C2 PTEN
CA RPTP, RPTP
CAAX box PRL-1, PRL-2, PRL-3
CH2 MKP-1 (DUSP1), PAC-1 (DUSP2), MKP-2 (DUSP4), hVH3/B23 (DUSP5), MKP-3 (DUSP6), MKP-X (DUSP7), hVH5,
(DUSP8), MKP-4 (DUSP9), MKP-5 (DUSP10), MKP-7 (DUSP16)
CRAL/TRIO PTP-MEG2
DNA binding Eya1-4
FERM PTPH1, PTP-MEG1, PTPD1, PEZ, PTP-BAS
FN CD45, LAR, RPTP, RPTP, RPTP, RPTP, RPTP, RPTP, RPTP, DEP1, SAP1, GLEPP1
FYVE HYVH1 (DUSP12), MTMR3, MTMR4
Ig LAR, RPTP, RPTP, RPTP, RPTP, RPTP, RPTP
KIM HePTP, STEP, PTP-SL
KIND PTP-BAS
MAM RPTP, RPTP, RPTP, RPTP,
mRNA capping mRNA capping enzyme
PBM PTEN, MTM1, MTMR1, MTMR2
PDZ PTPH1, PTP-MEG1, PTP-BAS
peptidase-like VHP
PH MTM1, MTMR1-13
PTB tensin, C1-ten
SH2 SHP1, SHP2, tensin, C1-ten
SH3B PTP-PEST, LYP, PEZ, DH-PTP
SH4 VHY (DUSP15), VHX (DUSP22)
a Abbreviations: BRO, baculovirus BRO homology; C1, protein kinase C conserved region 1; C2, protein kinase C conserved region 2; CA,
carbonic anhydrase-like; CAAX box, farnesylation signal; CH2, cdc25 homology region 2; CRAL/TRIO, cellular retinaldehyde binding protein/trio
homology (Sec14p homology); FERM, band 4.1/ezrin/radixin/moesin homology; FN, fibronectin-like; FYVE, Fab1/Yotb/Vac1p/early endosomal
antigen-1 homology; Ig, immunoglobulin-like; KIM, kinase interaction motif; KIND, kinase N lobe-like domain; MAM, meprin, A2, RPTP
homology; PBM, PDZ binding motif; PDZ, postsynaptic density-95/discs large/ZO1 homology; PH, pleckstrin homology (including GRAM
domains); PTB, phosphotyrosine-binding domain; SH2, src homology 2; SH3B, src homology 3 domain binding motif; SH4, src homology 4
(myristylation signal).
SH3-SH2 or SH2-SH2, only two human PTPs (SHP1 and classes of enzymes in temporally and spatially distinct
and often reciprocal manners.SHP2) have SH2 domains organized in a tandem fashion
like in the Syk family PTKs. Also, the catalytically inactive
PTEN-related tensin and C1-TEN have an SH2 domain Hints of Function from the
Multidomain Architectureadjacent to a PTB domain. In contrast, there are no
PTPs with SH3 domains. Conversely, there are no In many PTPs, the nature of their extracatalytic domains
gives some indications as to subcellular location or func-known kinases with CRAL/TRIO (Sec14p homology),
rhodanese, FYVE, or mRNA capping domains. Neverthe- tion. For example, all transmembrane classical PTPs
have a membrane-spanning  helix (by definition) andless, it is interesting to note that different domains may
serve similar functions in PTPs compared to PTKs. For are located in cellular membranes, mostly the plasma
membrane, where they interact with the extracellularexample, while PTKs mostly use PH domains to interact
with phosphoinositides, PTPs use CRAL/TRIO (Huynh milieu in a receptor-like fashion. All but RPTP and
RPTP have extended extracellular portions with immu-et al., 2003) and FYVE domains for the same purpose.
Only the myotubularins have PH domains, but it is un- noglobulin, fibronectin, MAM, and carbonic anhydrase
domains. Another example is laforin, a PTP that is mu-clear if they function to interact selectively with phos-
pholipid since myotubularins mostly do not localize to tated in an inherited form of progressive myoclonus
epilepsy (Lafora’s disease; Minassian et al., 1998), char-the plasma membrane. In fact, the PH domain of myotu-
bularins was referred to as a GRAM domain until the acterized histologically by accumulation of glycogen-
containing granules in the cytoplasm of cells. Recently,crystal structure of MTMR2 (Begley et al., 2003) showed
that this region folds as a PH domain. laforin was shown to contain a glycogen binding domain,
implying a direct role for laforin in glycogen metabolismPTPs also use FERM domains to direct them to the
cytoskeleton/plasma membrane interface in a phospho- (Wang et al., 2002). The 17 nonreceptor classical PTPs
are particularly rich in protein-protein interaction do-inositide-dependent manner, analogous to the use of
SH3, PH, and C2 domains by kinases. FERM domains mains and many of them have several such domains.
Within this group, SHP1 and SHP2 provide a good exam-may also be able to bind phosphotyrosine, and PTPs
may use catalytically inactive PTP (“STYX”) domains in ple of how protein-protein interaction domains can co-
operate with a PTP domain to achieve both intramolecu-a SH2-like manner to interact with tyrosine phosphory-
lated proteins (Wishart and Dixon, 1998). Together, lar regulation and targeting to substrates. In the absence
of ligands for the tandem SH2 domain of these PTPs,these differences in domain structure between PTPs
and PTKs may reflect the need to regulate these two the more N-terminal SH2 domain folds onto the catalytic
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Table 3. PTPs in Human Diseases Other than Cancer
PTPRC (CD45) SCID (Kung et al., 2000; Tchilian et al., 2001), multiple sclerosis (Jacobsen et al., 2000)
PTPRN (IA-2) Antigen for autoimmune diabetes (Solimena et al., 1996)
PTPRN2 (phogrin) Antigen for autoimmune diabetes (Kawasaki et al., 1996)
PTPN1 (PTP1B) Insulin resistance, obesity (Andersen et al., 2004)
PTPN6 (SHP1) Sezary syndrome (Andersen et al., 2004)
PTPN9 (PTP-MEG2) Autism (Smith et al., 2000)
PTPN11 (SHP2) Noonan syndrome (Tartaglia et al., 2001)
PTPN22 (LYP) SNP polymorphism in type I diabetes (Bottini et al., 2004)
PTEN (PTEN) Bannayan-Zonana (Marsh et al., 1997), Cowden syndrome and Lhermitte-Duclos disease
(Liaw et al., 1997)
MTM1 (myotubularin) X-linked myotubular myopathy (Laporte et al., 1996)
MTMR2 (MTMR2) Charcot-Marie-Tooth syndrome type 4B (Bolino et al., 2000)
MTMR13 (MTMR13) Charcot-Marie-Tooth syndrome type 4B (Azzedine et al., 2003)
EPM2A (laforin) Progressive myoclonus epilepsy (Lafora’s disease) (Minassian et al., 1998)
ACP1 (LMPTP) Polymorphism correlates with many common diseases (Bottini et al., 2002)
domain to block substrate access by the insertion of ity, but may lack some of the strict specificity and tight
regulation possible with single-chain multidomain PTPs.a loop on the backside of the SH2 domain into the
catalytic pocket of the PTP (Hof et al., 1998). When the In this context, it may also be significant that the atypical
DSP subgroup of PTPs contains many small enzymesSH2 domains of this inhibited form of SHP1 or SHP2
encounter a tyrosine phosphorylated ligand, the closed devoid of other domains or motifs. It is possible that
these enzymes participate in multisubunit complexesconformation opens and the enzyme is activated some
100-fold (Pei et al., 1994; Pluskey et al., 1995). Under where other subunits provide regulation and substrate
targeting. However, no examples of this have yet beenphysiological conditions, SH2 domain ligand binding
also juxtaposes the PTP domain to its substrates, which found.
contain, or associate with, the phosphorylated SH2 do-
main ligand. Catalytically Inactive PTP Domains
The DSP subfamily contains 11 members with a CH2 Among the class I cysteine-based PTPs, there are at
domain, a region derived from the bacterial rhodanese least 14 catalytically inactive PTP domains, in which
enzyme and adapted to a MAP kinase docking motif critical catalytic residues have been altered. These are
(Alonso et al., 2003b; Bordo and Bork, 2002). In CDC25, the second (D2) domains of CD45, RPTP, and RPTP,
on the other hand, the rhodanese has evolved into a and the only PTP domains of the secretory vesicle-
catalytic PTP domain (Bordo and Bork, 2002). Other located receptor-like PTP IA-2 (Solimena et al., 1996),
noncatalytic domains and motifs found in DSPs include a VHR-like protein termed STYX (Wishart et al., 1995),
FYVE, glycogen binding, mRNA capping (guanyl methyl- the MKP-like MK-STYX (Wishart and Dixon, 1998), the
transferase), and consensus recognition motifs for PTEN-related tensin and C1-ten, and the myotubularin-
N-terminal myristylation or C-terminal prenylation. PTEN related proteins MTMR5, MTMR9, MTMR11, MTMR12,
contains a C2 domain tightly packed against the PTP MTMR13 (Wishart and Dixon, 2002), and MTMR15. De-
domain, while members of the myotubularin family con- spite lack of catalytic activity, many of these proteins still
tain PH, FYVE, coiled-coil, and PDZ binding motifs play important roles in cells, in many cases by partnering
(Wishart and Dixon, 2002). A number of additional pro- with active PTPs. For example, CD45 needs its inactive
tein-protein interaction domains are found in PTPs in D2 domain for dephosphorylation by D1 of its physiolog-
other organisms, for example a WW domain in a ical substrates (Kashio et al., 1998). Similarly, the inac-
C. elegans PTP (Sudol, 1996), but are not present in tive MTMRs seem to act as important regulatory sub-
the human PTPs either because they have been lost or units for active members of the group, as shown by the
because they evolved in a separate lineage. human disease Charcot-Marie-Tooth type 4B, which is
caused by mutation of the catalytically active MTMR2
(Bolino et al., 2000) or the catalytically inactive MTMR13Large Multidomain PTPs versus Multisubunit
Ser/Thr Phosphatases (Azzedine et al., 2003), in both cases with identical pa-
thology and symptoms. It turns out that these two pro-The multidomain structure of most PTPs is in sharp
contrast to the serine/threonine protein phosphatases, teins form a heterodimer, in which the activity of MTMR2
depends on MTMR13. There are similar examples wherewhich generally consist of small catalytic subunits that
bind regulatory or targeting subunits encoded by sepa- an inactive kinase domain is needed to activate a cata-
lytically competent kinase domain; e.g., LKB1 is acti-rate genes to form a large number of distinct holoen-
zymes with different biological functions. This dichot- vated by STRAD (Baas et al., 2003). In addition to these
inherently inactive PTP domains, alternative splicing ofomy may explain the differences in gene numbers: 107
PTPs to counteract 90 PTKs versus many fewer catalytic PTP transcripts (which occurs in at least half of all PTPs)
can create isoforms that have catalytically inactive PTPSer/Thr phosphatase subunits to counter 428 protein
kinases and the extensive phosphorylation of more than domains (Tailor et al., 1999), or lack them altogether
(Bult et al., 1997). Physiologically important alternativea third of all cellular proteins. Presumably, the combina-
torial subunit principle of serine/threonine protein phos- splicing within the catalytic domains is known to create
two isoforms of the class II enzyme LMPTP with differentphatases can generate much more diversity and flexibil-
Cell
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Figure 3. Surface Charge and Topology of a Set of Class I Twelve PTP Domains
These structures were modeled using the crystal structures of PTPs, and the models are colored according to charge of surface-exposed
amino acid residues.
specific activity, substrate specificity, and regulation carbohydrates in their extracellular portions. Two groups
of DSPs are modified by fatty acids: VHY (DUSP15) and(Mitchell Bryson et al., 1995). In this enzyme, the ratio
of the two isoforms is genetically determined and sub- VHX (DUSP22) are N-terminally myristylated in a manner
reminiscent of Src family PTKs (Alonso et al., 2004),ject to allelic variation, which correlates with the predis-
position to several common human diseases (Bottini et while the PRLs are C-terminally farnesylated similar to
Ras GTPases. By far the most common modification isal., 2002).
the phosphorylation of PTPs on serine, threonine, and
tyrosine. There are many examples where Ser/Thr phos-Posttranslational Modifications and Reversible
Oxidation of PTPs phorylation has been shown to regulate activity. The
phosphorylation of PTPs on tyrosine is particularly intri-The majority of PTPs are posttranslationally modified.
Glycosylation appears to be restricted to the transmem- guing as it implies a physical, if not functional, interac-
tion with PTKs (Mustelin and Hunter, 2002). At least 15brane PTPs, which contain abundant N- and O-linked
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PTPs have been reported to be tyrosine phosphorylated, PTP domains to illustrate the striking diversity within
the class I PTPs. For example, for PTP1B it was foundbut the physiological significance remains unclear in
most cases. Tyrosine phosphorylation also introduces that a unique second PTyr binding site (Puius et al.,
1997; Salmeen et al., 2000) could be used to developthe possibility of autodephosphorylation. In fact, many
PTPs become noticeably more phosphorylated on tyro- highly specific bidentate inhibitors that bind both sites
(Zhang, 2002). This general approach can be used tosine when expressed as catalytically inactive mutants.
In most cases, however, the phosphorylation sites are design highly specific and effective inhibitors.
clearly inaccessible for intramolecular dephosphoryla-
tion, suggesting that dephosphorylation must occur in Concluding Remarks
trans. Thus, regulatory networks of PTPs and other pro- The main challenge now facing the PTP field in the post-
tein phosphatases, perhaps in the form of “phosphatase genomic era is to elucidate the physiological role of
cascades,” may exist in cells. each individual gene product. This task is multiplied by
It has been known for many years that the catalytic the capacity of many PTP genes to generate alterna-
cysteine of class I and II PTPs is highly susceptible to tively spliced products, the existence of single-nucleo-
oxidation in vitro, and it has been speculated that this tide polymorphisms that alter function, and the regula-
could play a role in intact cells exposed to oxidizing tory influences of many posttranslational modifications
agents. An exciting new development was the discovery and protein-protein interactions. The rate of progress is
that oxidation of PTP1B does not result in a stable sul- likely to be accelerated by many emerging new technol-
fenic acid derivative of the catalytic site cysteine, but ogies. The identification of the physiological substrates
rapidly transforms into a sulfenyl amide ring involving for all PTPs is an important task likely to be aided by
the adjacent serine residue (Salmeen et al., 2003; van the development of mass spectrometry technologies to
Montfort et al., 2003). This form is resistant to further study the entire phosphoproteome of cells in a compre-
oxidation, which would be irreversible, and is readily hensive, detailed, and quantitative manner. Genetic ap-
reduced back to the free cysteinyl, catalytically active proaches and RNA interference will likely promote dis-
form. Together with recent insights into the production covery of physiological functions and will help to
of reactive oxygen species and nitrogen oxides in cells address important questions of redundancy. All these
during growth factor stimulation in cancer, inflamma- issues are important for the full utilization of PTP as
tion, and neurodegenerative diseases, it now seems drug targets and the treatment of many human diseases
likely that reversible redox regulation of PTPs occurs in in which PTPs play regulatory or even causative roles.
intact cells. Since PTPs often play dominant roles in
setting the levels of tyrosine phosphorylation in cells, References
this regulation may be physiologically very important.
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